Bristol Myers Squibb Company $BMY Stake Lifted by Leuthold Group LLC

Leuthold Group LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 9.7% in the third quarter, HoldingsChannel reports. The firm owned 107,316 shares of the biopharmaceutical company’s stock after purchasing an additional 9,447 shares during the period. Leuthold Group LLC’s holdings in Bristol Myers Squibb were worth $6,697,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of BMY. BlackRock Inc. grew its position in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares in the last quarter. State Street Corp increased its stake in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after buying an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA acquired a new stake in Bristol Myers Squibb in the second quarter valued at $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after acquiring an additional 119,690 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Bristol Myers Squibb by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after acquiring an additional 520,330 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BMY shares. The Goldman Sachs Group raised shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Friday, October 16th. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. JPMorgan Chase & Co. increased their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Morgan Stanley decreased their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research note on Friday, October 30th. Finally, Guggenheim reiterated a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $65.46.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This represents a 11.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Performance

BMY stock opened at $62.16 on Tuesday. The stock’s 50 day simple moving average is $62.25 and its 200 day simple moving average is $60.15. Bristol Myers Squibb Company has a 12-month low of $45.26 and a 12-month high of $68.64. The firm has a market cap of $127.06 billion, a P/E ratio of 13.78, a P/E/G ratio of 0.33 and a beta of 0.20. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the previous year, the company posted $1.63 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts predict that Bristol Myers Squibb Company will post 6.45 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s payout ratio is 55.88%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.